Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUSNASDAQ:EPIXNASDAQ:FIXXNASDAQ:INZYNASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsEPIXESSA Pharma$1.70-1.7%$1.71$1.40▼$7.88$76.79M1.59339,218 shs39,329 shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsINZYInozyme Pharma$4.00+0.3%$2.97$0.72▼$6.24$257.60M2.27917,357 shs1.46 million shsRIGLRigel Pharmaceuticals$18.73-3.9%$19.51$7.48▼$29.82$348.15M1.29210,930 shs292,775 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma0.00%0.00%+2.98%+9.49%-67.11%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%INZYInozyme Pharma0.00%0.00%+1.01%+338.46%-10.54%RIGLRigel Pharmaceuticals0.00%+2.91%+0.93%+8.28%+136.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AEPIXESSA Pharma1.9728 of 5 stars2.02.00.00.03.32.51.3FIXXHomology Medicines0.6888 of 5 stars0.00.00.04.80.60.80.6INZYInozyme Pharma3.5402 of 5 stars4.24.00.00.02.72.50.0RIGLRigel Pharmaceuticals2.8223 of 5 stars3.20.00.00.01.61.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/AEPIXESSA Pharma 2.00Hold$2.0017.65% UpsideFIXXHomology Medicines 0.00N/AN/AN/AINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4094.34% UpsideCurrent Analyst Ratings BreakdownLatest FIXX, INZY, EPIX, RIGL, and AKUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.004/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/8/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00INZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ARIGLRigel Pharmaceuticals$179.28M1.87$1.04 per share18.06$0.19 per share98.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AEPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AINZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$2.079.0517.84N/A18.31%-655.26%24.47%8/5/2025 (Estimated)Latest FIXX, INZY, EPIX, RIGL, and AKUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30EPIXESSA PharmaN/A67.1567.15FIXXHomology MedicinesN/A7.257.25INZYInozyme Pharma0.652.192.19RIGLRigel Pharmaceuticals2.422.202.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/AEPIXESSA Pharma75.12%FIXXHomology Medicines31.32%INZYInozyme Pharma88.30%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%EPIXESSA Pharma15.50%FIXXHomology Medicines16.10%INZYInozyme Pharma12.18%RIGLRigel Pharmaceuticals9.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.26 millionOptionableFIXX, INZY, EPIX, RIGL, and AKUS HeadlinesRecent News About These CompaniesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Hold" by BrokeragesJune 27 at 4:31 AM | marketbeat.comRIGL Rigel Pharmaceuticals, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) shareholders have earned a 99% return over the last yearJune 21, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stake Boosted by GAMMA Investing LLCJune 21, 2025 | marketbeat.comRigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potentialJune 14, 2025 | investing.comAssenagon Asset Management S.A. Buys 112,003 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 14, 2025 | marketbeat.comCantor Fitzgerald Weighs in on RIGL FY2026 EarningsJune 10, 2025 | marketbeat.comWellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 8, 2025 | marketbeat.comTwo Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 6, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLCJune 6, 2025 | marketbeat.comMillennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $676,000 in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 4, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Hold" from BrokeragesJune 2, 2025 | marketbeat.comSquarepoint Ops LLC Purchases 18,159 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comIs Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?May 29, 2025 | zacks.comWall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?May 28, 2025 | zacks.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFIXX, INZY, EPIX, RIGL, and AKUS Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.ESSA Pharma NASDAQ:EPIX$1.70 -0.03 (-1.73%) As of 04:00 PM EasternESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Inozyme Pharma NASDAQ:INZY$4.00 +0.01 (+0.25%) As of 04:00 PM EasternInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$18.73 -0.75 (-3.85%) As of 04:00 PM EasternRigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
